This grant, part of DARPA’s Hermes program, is for developing innovative systemic drug delivery platforms essential for medical countermeasures (MCMs). DARPA seeks transformative approaches that achieve exceptional systemic biodistribution, high endosomal escape efficiency, and minimal toxicity. Proposals should detail a robust screening pipeline, effective reporter systems for monitoring biodistribution and expression in animal models, and comprehensive methods for assessing immunogenicity and toxicity. Applicants must also justify their chosen therapeutic cargo. Successful platforms developed under this effort will be transferred to U.S. Government stakeholders for further development, advancing critical capabilities in medical defense.
Opportunity ID: 353643
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HR001124S0025 |
| Funding Opportunity Title: | Hermes |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Apr 19, 2024 |
| Last Updated Date: | May 14, 2024 |
| Original Closing Date for Applications: | Jun 04, 2024 See Full Announcement for details. |
| Current Closing Date for Applications: | Jun 11, 2024 See Full Announcement for details. |
| Archive Date: | Jul 04, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | All responsible sources capable of satisfying the Government’s needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information. |
Additional Information
| Agency Name: | DARPA – Biological Technologies Office |
| Description: | The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to develop systemic drug delivery platforms for medical countermeasures (MCMs). The Hermes program is explicitly seeking transformative approaches enabling the development of delivery platforms with systemic biodistribution, exceptional endosomal escape efficiency, and minimal toxicity. Successful proposals will include a detailed description of the proposed delivery platform including 1) screening pipeline, 2) reporter systems for monitoring biodistribution and expression in animal models, 3) methods to monitor immunogenicity/toxicity, and 4) chosen therapeutic cargo and justification. Systemic delivery platforms developed under the Hermes effort will be transferred to U.S. Government stakeholders for further development. |
| Link to Additional Information: | SAM.gov Contract Opportunities |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Dr. Shannon Greene
HermesBAA@darpa.mil Email:HermesBAA@darpa.mil |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The purpose of Amendment 1 to HR001124S0025, the Hermes Broad Agency Announcement, is to extend the full proposal deadline. | May 14, 2024 | |
| Apr 19, 2024 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HR001124S0025 |
| Funding Opportunity Title: | Hermes |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Apr 19, 2024 |
| Last Updated Date: | May 14, 2024 |
| Original Closing Date for Applications: | Jun 04, 2024 See Full Announcement for details. |
| Current Closing Date for Applications: | Jun 11, 2024 See Full Announcement for details. |
| Archive Date: | Jul 04, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | All responsible sources capable of satisfying the Government’s needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information. |
Additional Information
| Agency Name: | DARPA – Biological Technologies Office |
| Description: | The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to develop systemic drug delivery platforms for medical countermeasures (MCMs). The Hermes program is explicitly seeking transformative approaches enabling the development of delivery platforms with systemic biodistribution, exceptional endosomal escape efficiency, and minimal toxicity. Successful proposals will include a detailed description of the proposed delivery platform including 1) screening pipeline, 2) reporter systems for monitoring biodistribution and expression in animal models, 3) methods to monitor immunogenicity/toxicity, and 4) chosen therapeutic cargo and justification. Systemic delivery platforms developed under the Hermes effort will be transferred to U.S. Government stakeholders for further development. |
| Link to Additional Information: | SAM.gov Contract Opportunities |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Dr. Shannon Greene
HermesBAA@darpa.mil Email:HermesBAA@darpa.mil |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HR001124S0025 |
| Funding Opportunity Title: | Hermes |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 19, 2024 |
| Last Updated Date: | Apr 19, 2024 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jun 04, 2024 See Full Announcement for details. |
| Archive Date: | Jul 04, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | All responsible sources capable of satisfying the Government’s needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information. |
Additional Information
| Agency Name: | DARPA – Biological Technologies Office |
| Description: | The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to develop systemic drug delivery platforms for medical countermeasures (MCMs). The Hermes program is explicitly seeking transformative approaches enabling the development of delivery platforms with systemic biodistribution, exceptional endosomal escape efficiency, and minimal toxicity. Successful proposals will include a detailed description of the proposed delivery platform including 1) screening pipeline, 2) reporter systems for monitoring biodistribution and expression in animal models, 3) methods to monitor immunogenicity/toxicity, and 4) chosen therapeutic cargo and justification. Systemic delivery platforms developed under the Hermes effort will be transferred to U.S. Government stakeholders for further development. |
| Link to Additional Information: | SAM.gov Contract Opportunities |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Dr. Shannon Greene
HermesBAA@darpa.mil Email:HermesBAA@darpa.mil |
Related Documents
Folder 353643 Full Announcement-HR001124S0025 -> HERMES_BAA_Attachment_D_Proposal_Instructions_and_Volume_I_Template__Technical_and_Management.pdf
Folder 353643 Full Announcement-HR001124S0025 -> HERMES_BAA_Attachment_B_Abstract_Instructions_and_Template.pdf
Folder 353643 Full Announcement-HR001124S0025 -> HERMES_BAA_Attachment_F_DARPAStandardCostProposalSpreadsheetSingleTA.pdf
Folder 353643 Full Announcement-HR001124S0025 -> HERMES_BAA_Attachment_A_Abstract_Summary_Side_Template.pdf
Folder 353643 Full Announcement-HR001124S0025 -> HERMES_BAA_Attachment_E_Proposal_Instructions_and_Volume_II_Template__Cost.pdf
Folder 353643 Full Announcement-HR001124S0025 -> HERMES_BAA_Attachment_C_Proposal_Summary_Slide_Template.pdf
Folder 353643 Full Announcement-HR001124S0025 -> HR001124S0025.pdf
Folder 353643 Revised Full Announcement-HR001124S0025-Amendment-01 -> HR001124S0025-Amendment-01.pdf
Packages
| Agency Contact Information: | Dr. Shannon Greene HermesBAA@darpa.mil Email: HermesBAA@darpa.mil |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.910 | PKG00285954 | May 14, 2024 | Jun 11, 2024 | View |
Package 1
Mandatory forms
353643 RR_SF424_5_0-5.0.pdf
353643 RR_KeyPersonExpanded_4_0-4.0.pdf
353643 RR_PersonalData_1_2-1.2.pdf
Optional forms
353643 AttachmentForm_1_2-1.2.pdf
353643 RR_OtherProjectInfo_1_4-1.4.pdf
353643 PerformanceSite_4_0-4.0.pdf
353643 SFLLL_2_0-2.0.pdf
353643 Key_Contacts_2_0-2.0.pdf
353643 Project_Abstract_1_2-1.2.pdf
353643 RR_Budget10_3_0-3.0.pdf
353643 RR_SubawardBudget10_30_3_0-3.0.pdf
353643 RR_Budget_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
